About Mark Finn
Form D filings for Metabolics Pharma in 2024 list Mark Finn as director.
Form D filings also name Mark Finn as a director at Enterin.
Mark Finn first appears on SEC filings in 2017.
Experience
This experience comes from SEC filings. The years are when the filings name Mark Finn in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Mark Finn works with at each company, as listed on that company's latest Form D.
Metabolics Pharma, Inc. · Form D, Sep 19, 2024
MK
Mark Kamp
Director
JD
John Dessouki
Executive officer and director
BM
Barry Miller
Director
JB
Jay Brammer
Director
RL
Richard Larson
Chief Executive Officer and director
Enterin, Inc. · Form D, Dec 6, 2023
MZ
Michael Zasloff
Director
DM
David McCullough
Chief Executive Officer and director
BM
Barry Miller
Director
DM
Don Munoz
Director
KW
Katherine Wolf
Executive officer
RL
Richard Larson
Executive officer
RM
Roger Mills
Director
WK
William Kinney
Executive officer
JB
Jay Brammer
Director
RP
Richard Propper
Director